Polymyxin B and fusidic acid, a novel potent synergistic combination against
Klebsiella pneumoniae
fusidic acid
polymyxin B
resistance
synergistic effect
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
05
2023
accepted:
26
09
2023
medline:
27
10
2023
pubmed:
27
10
2023
entrez:
27
10
2023
Statut:
epublish
Résumé
The increasing prevalence of multidrug-resistant (MDR) Gram-negative bacteria and comparatively limited options of antibiotics pose a major threat to public health worldwide. Polymyxin B is the last resort against extensively resistant Gram-negative bacterial infections. However, a large number of Gram-negative bacteria exhibited high-level resistance to Polymyxin B, bringing challenges for antimicrobial chemotherapy. Combination therapies using polymyxins and other antibiotics are recommended to treat multidrug-resistant pathogens. In this study, we selected Gram-negative bacterial strains, including
Identifiants
pubmed: 37886061
doi: 10.3389/fmicb.2023.1220683
pmc: PMC10598591
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1220683Informations de copyright
Copyright © 2023 Chen, Zhou, Wu, Wang, Zhou, Zhang, Wang, Zhao, Rao, Li, Yu and Lin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Rep. 2021 May 31;11(1):11339
pubmed: 34059725
Clin Microbiol Infect. 2012 Jan;18(1):30-9
pubmed: 21988234
Pharmacotherapy. 2010 Dec;30(12):1279-91
pubmed: 21114395
Lancet Infect Dis. 2006 Sep;6(9):589-601
pubmed: 16931410
Drugs. 2022 Apr;82(5):533-557
pubmed: 35294769
J Antimicrob Chemother. 2012 Jul;67(7):1607-15
pubmed: 22441575
Antimicrob Agents Chemother. 2003 Jan;47(1):418-20
pubmed: 12499229
J Chem Inf Model. 2020 Oct 26;60(10):4975-4984
pubmed: 33017152
Clin Pharmacokinet. 2017 Dec;56(12):1441-1460
pubmed: 28550595
Clin Infect Dis. 2011 Jun;52 Suppl 7:S542-6
pubmed: 21546632
Cold Spring Harb Perspect Med. 2016 Jan 04;6(1):a025437
pubmed: 26729758
Am J Health Syst Pharm. 2007 Dec 1;64(23):2462-6
pubmed: 18029951
Clin Infect Dis. 2011 Jun;52 Suppl 7:S527-37
pubmed: 21546630
J Antimicrob Chemother. 2019 Apr 1;74(4):961-969
pubmed: 30624656
Curr Opin Infect Dis. 2009 Dec;22(6):535-43
pubmed: 19797945
Antimicrob Agents Chemother. 2011 Jul;55(7):3284-94
pubmed: 21555763
Acta Biochim Pol. 2015;62(4):867-74
pubmed: 26637376
Clin Microbiol Infect. 2022 Jul;28(7):1026.e1-1026.e5
pubmed: 35283314
BMC Microbiol. 2020 Oct 12;20(1):306
pubmed: 33045992
Front Cell Infect Microbiol. 2017 Nov 21;7:483
pubmed: 29209595
Microbiol Spectr. 2021 Oct 31;9(2):e0015221
pubmed: 34704782
Antibiotics (Basel). 2019 Aug 19;8(3):
pubmed: 31430964
PLoS One. 2022 Jul 13;17(7):e0270908
pubmed: 35830449
Curr Opin Infect Dis. 2012 Dec;25(6):626-33
pubmed: 23041772
Int J Mol Sci. 2022 Jul 22;23(15):
pubmed: 35897667
Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):59-71
pubmed: 27573251
Clin Microbiol Infect. 2016 May;22(5):398-400
pubmed: 27021419
Adv Exp Med Biol. 2019;1145:197-218
pubmed: 31364080
Biochem Biophys Res Commun. 1968 Dec 9;33(5):769-73
pubmed: 4881331
Adv Exp Med Biol. 2019;1145:55-71
pubmed: 31364071
Int J Environ Res Public Health. 2020 Aug 28;17(17):
pubmed: 32872324
J Antimicrob Chemother. 2008 Mar;61(3):636-42
pubmed: 18227094
J Appl Microbiol. 2022 Feb;132(2):1036-1047
pubmed: 34496109
Rev Chilena Infectol. 2016 Apr;33(2):166-76
pubmed: 27314994
Antimicrob Agents Chemother. 2013 Jan;57(1):498-507
pubmed: 23147726
Front Cell Infect Microbiol. 2022 Aug 26;12:941358
pubmed: 36093193
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29203488